Table 3.

Risk of AML bleeding stratified by growth/no growth. From Cox et al. [2012].

9.5 Year Follow Up (n = 54)

• Growth 34 (63%)

• bleed 11 (20%)/3 (6%) commenced mTOR inhibitor

• no bleed 20 (37%)

• No growth 20 (37%)

• bleed 2 (4%)

• no bleed 18 (33%)

χ2 = 6.7, p < 0.01

• NNT: for patients with growing AMLs, the NNT to prevent one bleed is 3.2

AML, angiomyolipoma; mTOR, mammalian target of rapamycin; NNT, number needed to treat.